WO2001095230A3 - Method for predicting therapeutic agent resistance using neural networks - Google Patents

Method for predicting therapeutic agent resistance using neural networks Download PDF

Info

Publication number
WO2001095230A3
WO2001095230A3 PCT/EP2001/006360 EP0106360W WO0195230A3 WO 2001095230 A3 WO2001095230 A3 WO 2001095230A3 EP 0106360 W EP0106360 W EP 0106360W WO 0195230 A3 WO0195230 A3 WO 0195230A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
disease
resistance
neural network
predicting
Prior art date
Application number
PCT/EP2001/006360
Other languages
French (fr)
Other versions
WO2001095230A2 (en
Inventor
Brendan Larder
Dechao Wang
Original Assignee
Virco Bvba
Brendan Larder
Dechao Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/589,167 external-priority patent/US7058616B1/en
Application filed by Virco Bvba, Brendan Larder, Dechao Wang filed Critical Virco Bvba
Priority to AU67520/01A priority Critical patent/AU785353B2/en
Priority to CA2415832A priority patent/CA2415832C/en
Priority to US10/297,338 priority patent/US20030190603A1/en
Priority to EP01945251A priority patent/EP1352356B1/en
Priority to DE60140211T priority patent/DE60140211D1/en
Priority to AT01945251T priority patent/ATE445883T1/en
Priority to JP2002502695A priority patent/JP4726177B2/en
Publication of WO2001095230A2 publication Critical patent/WO2001095230A2/en
Publication of WO2001095230A3 publication Critical patent/WO2001095230A3/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Bioethics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method and system for predicting the resistance of a disease to a therapeutic agent is provided. Further provided is a method and system for designing a therapeutic treatment agent for a patient afflicted with a disease. Specifically, the methods use a trained neural network to interpret genotypic information obtained from the disease. The trained neural network is trained using a database of known or determined genotypic mutations that are correlated with phenotypic therapeutic agent resistance. The present invention also provides methods and systems for predicting the probability of a patient developing a genetic disease. A trained neural network for making such predictions is also provided. Also provided is a method and system for determining the genetic basis of therapeutic agent resistance.
PCT/EP2001/006360 2000-06-08 2001-06-01 Method for predicting therapeutic agent resistance using neural networks WO2001095230A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU67520/01A AU785353B2 (en) 2000-06-08 2001-06-01 Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
CA2415832A CA2415832C (en) 2000-06-08 2001-06-01 Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
US10/297,338 US20030190603A1 (en) 2000-06-08 2001-06-01 Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
EP01945251A EP1352356B1 (en) 2000-06-08 2001-06-01 Method for predicting therapeutic agent resistance using neural networks
DE60140211T DE60140211D1 (en) 2000-06-08 2001-06-01 PROCEDURE FOR RESISTANCE TO A THERAPEUTIC AGENCY PREDICTED BY NEURONAL NETWORKS
AT01945251T ATE445883T1 (en) 2000-06-08 2001-06-01 METHOD FOR PREDICTING RESISTANCE TO A THERAPEUTIC AGENT USING NEURONAL NETWORKS
JP2002502695A JP4726177B2 (en) 2000-06-08 2001-06-01 Method and system for predicting therapeutic drug resistance using neural networks and defining the genetic basis of drug resistance

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/589,167 2000-06-08
US09/589,167 US7058616B1 (en) 2000-06-08 2000-06-08 Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
US24184400P 2000-10-20 2000-10-20
US24180100P 2000-10-20 2000-10-20
US60/241,801 2000-10-20
US60/241,844 2000-10-20

Publications (2)

Publication Number Publication Date
WO2001095230A2 WO2001095230A2 (en) 2001-12-13
WO2001095230A3 true WO2001095230A3 (en) 2003-08-21

Family

ID=27399520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/006360 WO2001095230A2 (en) 2000-06-08 2001-06-01 Method for predicting therapeutic agent resistance using neural networks

Country Status (9)

Country Link
US (1) US20030190603A1 (en)
EP (1) EP1352356B1 (en)
JP (1) JP4726177B2 (en)
AT (1) ATE445883T1 (en)
AU (1) AU785353B2 (en)
CA (1) CA2415832C (en)
DE (1) DE60140211D1 (en)
ES (1) ES2334011T3 (en)
WO (1) WO2001095230A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0011555A (en) 1999-05-28 2002-02-26 Virco Nv Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
AU1234402A (en) * 2000-10-20 2002-04-29 Virco Nv Establishment of biological cut-off values for predicting resistance to therapy
WO2002033638A2 (en) * 2000-10-20 2002-04-25 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
FI20021031A (en) * 2001-12-28 2003-06-29 Pertti Laehteenmaeki Nutritional Machine
FI20012593A0 (en) 2001-12-28 2001-12-28 Pertti Laehteenmaeki A method and system for providing a nutrition information service
WO2004003817A1 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US7473524B2 (en) 2002-07-01 2009-01-06 Hilde Azijn Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
US7194320B2 (en) * 2003-06-05 2007-03-20 Neuco, Inc. Method for implementing indirect controller
EP1681981A4 (en) * 2003-10-10 2008-04-23 Biophysical Corp Generation of biochemical images and methods of use
JP2007523397A (en) * 2004-01-05 2007-08-16 タイトガット，ディダー Multi-agent system based on behavior as data type
US8214271B2 (en) 2004-02-04 2012-07-03 Neuco, Inc. System and method for assigning credit to process inputs
EP1728186A2 (en) 2004-03-02 2006-12-06 Virco Bvba Estimation of clinical cut-offs
US7333861B2 (en) * 2004-10-25 2008-02-19 Neuco, Inc. Method and system for calculating marginal cost curves using plant control models
WO2007035719A2 (en) * 2005-09-19 2007-03-29 University Of Houston High throughput screening for antimicrobial dosing regimens
US20140011762A1 (en) * 2005-09-19 2014-01-09 Vincent H. Tam High Throughput Screening for Antimicrobial Dosing Regimens
WO2012014082A2 (en) * 2010-07-28 2012-02-02 Purapharm International (Hk) Limited Artificial intelligence and methods for relating herbal ingredients with illnesses in traditional chinese medicine
US8918352B2 (en) * 2011-05-23 2014-12-23 Microsoft Corporation Learning processes for single hidden layer neural networks with linear output units
US9336483B1 (en) * 2015-04-03 2016-05-10 Pearson Education, Inc. Dynamically updated neural network structures for content distribution networks
US10762982B1 (en) * 2015-10-07 2020-09-01 Trace Genomics, Inc. System and method for nucleotide analysis
US10629291B2 (en) * 2016-03-10 2020-04-21 Koninklijke Philips N.V. Antibiotic resistance causation identification
CN110024036B (en) * 2016-11-28 2023-06-30 皇家飞利浦有限公司 Analytical prediction of antibiotic susceptibility
CN106640066B (en) * 2016-12-28 2019-08-30 贵州大学 A kind of method of determining girdle flitting fully mechanized mining mode
US10235622B2 (en) * 2017-01-24 2019-03-19 Sas Institute Inc. Pattern identifier system
US20210097389A1 (en) * 2017-02-07 2021-04-01 Qatar University Generalized operational perceptrons: new generation artificial neural networks
US20180330059A1 (en) * 2017-05-09 2018-11-15 James Stewart Bates Patient treatment systems and methods
US9922285B1 (en) * 2017-07-13 2018-03-20 HumanCode, Inc. Predictive assignments that relate to genetic information and leverage machine learning models
CN107742151A (en) * 2017-08-30 2018-02-27 电子科技大学 A kind of neural network model training method of Chinese medicine pulse
WO2019050902A1 (en) * 2017-09-05 2019-03-14 Adaptive Phage Therapeutics, Inc. Methods to determine the sensitivity profile of a bacterial strain to a therapeutic composition
US11694773B2 (en) 2019-03-01 2023-07-04 Sanofi Methods to estimate effectiveness of a medical treatment
WO2022087540A1 (en) * 2020-10-23 2022-04-28 The Regents Of The University Of California Visible neural network framework
CN113077849B (en) * 2021-03-16 2023-03-31 华南农业大学 Escherichia coli beta-lactam acquired drug resistance phenotype prediction composite method
CN113966999A (en) * 2021-10-28 2022-01-25 中山大学 Sorafenib drug resistance prediction method and device and storage medium
CN114726419A (en) * 2022-04-07 2022-07-08 重庆邮电大学 Conjugate gradient large-scale MIMO detection method based on deep learning

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029447A2 (en) * 1996-02-09 1997-08-14 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
WO1998054669A1 (en) * 1997-05-28 1998-12-03 Amersham Pharmacia Biotech Ab A method and a system for nucleic acid sequence analysis
WO1999066302A2 (en) * 1998-06-17 1999-12-23 Musc Foundation For Research Development Recognition of protein coding regions in genomic dna sequences

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5862304A (en) * 1990-05-21 1999-01-19 Board Of Regents, The University Of Texas System Method for predicting the future occurrence of clinically occult or non-existent medical conditions
SE504769C2 (en) * 1994-03-17 1997-04-21 Agrovision Ab Method and apparatus for automatic assessment of cereals
JPH08110896A (en) * 1994-10-10 1996-04-30 Nippondenso Co Ltd Feedforward type neural network
AU1837495A (en) * 1994-10-13 1996-05-06 Horus Therapeutics, Inc. Computer assisted methods for diagnosing diseases
US5930154A (en) * 1995-01-17 1999-07-27 Intertech Ventures, Ltd. Computer-based system and methods for information storage, modeling and simulation of complex systems organized in discrete compartments in time and space
JP3786442B2 (en) * 1995-01-23 2006-06-14 帝人株式会社 Drug sensitivity prediction method
US5845049A (en) * 1996-03-27 1998-12-01 Board Of Regents, The University Of Texas System Neural network system with N-gram term weighting method for molecular sequence classification and motif identification
US5953727A (en) * 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US5945289A (en) * 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5860917A (en) * 1997-01-15 1999-01-19 Chiron Corporation Method and apparatus for predicting therapeutic outcomes
CA2276064C (en) * 1997-01-17 2013-12-17 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
JP2001512036A (en) * 1997-07-30 2001-08-21 バイアラジック・インコーポレーテッド Compositions and methods for measuring antiviral drug susceptibility and resistance, and compositions and methods for screening antiviral drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029447A2 (en) * 1996-02-09 1997-08-14 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
WO1998054669A1 (en) * 1997-05-28 1998-12-03 Amersham Pharmacia Biotech Ab A method and a system for nucleic acid sequence analysis
WO1999066302A2 (en) * 1998-06-17 1999-12-23 Musc Foundation For Research Development Recognition of protein coding regions in genomic dna sequences

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AJAY: "A unified framework for using neural networks to build QSARs.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 23, 1993, pages 3565 - 3571, XP002245717, ISSN: 0022-2623 *
ARTIFICIAL LIFE, vol. 4, no. 1, 1 January 1998 (1998-01-01), pages 41 - 59, ISSN: 1064-5462 *
BINARY COMPUTING IN MICROBIOLOGY, vol. 7, no. 4-6, 1995, pages 159 - 166, ISSN: 1057-350X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1 January 1998 (1998-01-01), ROSIN CHRISTOPHER D ET AL: "Computational coevolution of antiviral drug resistance.", XP002245720, Database accession no. PREV199800507252 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, ALMEIDA JONAS S ET AL: "Application of artificial neural networks to the detection of Mycobacterium tuberculosis, its antibiotic resistance and prediction of pathogenicity amongst Mycobacterium spp. based on signature lipid biomarkers.", XP002245721, Database accession no. PREV199698729308 *
GOODACRE ROYSTON ET AL: "Discrimination between methicillin-resistant and methicillin-susceptible Staphylococcus aureus using pyrolysis mass spectrometry and artificial neural networks.", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 41, no. 1, January 1998 (1998-01-01), pages 27 - 34, XP002245718, ISSN: 0305-7453 *
YAO XIAO-JIAN ET AL: "Degradation of CD4 induced by human immunodeficiency virus type 1 Vpu protein: A predicted alpha-helix structure in the proximal cytoplasmic region of CD4 contributes to Vpu sensitivity.", VIROLOGY, vol. 209, no. 2, 1995, pages 615 - 623, XP002245719, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
JP2004523725A (en) 2004-08-05
WO2001095230A2 (en) 2001-12-13
CA2415832C (en) 2012-07-24
JP4726177B2 (en) 2011-07-20
AU785353B2 (en) 2007-02-01
US20030190603A1 (en) 2003-10-09
AU6752001A (en) 2001-12-17
ATE445883T1 (en) 2009-10-15
CA2415832A1 (en) 2001-12-13
EP1352356A2 (en) 2003-10-15
ES2334011T3 (en) 2010-03-04
DE60140211D1 (en) 2009-11-26
EP1352356B1 (en) 2009-10-14

Similar Documents

Publication Publication Date Title
WO2001095230A3 (en) Method for predicting therapeutic agent resistance using neural networks
WO2003001327A3 (en) Intelligent caching and network management based on location and resource anticipation
WO2003039234A3 (en) Pharmacogenomics-based system for clinical applications
BRPI0410229A (en) method for providing information associated with target user location, location service entity, and location service for providing information associated with communication system users
EP1274012A3 (en) Method and system for establishing a quorum for a geographically distributed cluster of computers
DK0842475T3 (en) Computer-aided methods and apparatus for diagnosing diseases
EP0883068A3 (en) Entity retrieving system and method for retrieving entities
WO2002082771A3 (en) Method and system for providing and updating electronic contact information from a central source
Cornelissen et al. The arthritis sufferer and the community: a comparison of arthritis sufferers in rural and urban areas.
WO2001016860A3 (en) Artificial intelligence system for genetic analysis
WO2002023186A3 (en) System and method for optimizing drug therapy for the treatment of diseases
ATE527827T1 (en) METHOD AND DEVICE FOR HEARING AID ADJUSTMENT
WO2002048831A3 (en) Method, apparatus, and system for aggregating, targeting, and synchronizing health information delivery
HK1066076A1 (en) Method and system for modeling and managing terrain, buildings, and infrastructure
EP0876072A3 (en) Variable radio interface
WO2003004696A3 (en) A distributed system for epigenetic based prediction of complex phenotypes
BR9811441A (en) Protection method to identify individuals at risk of developing diseases associated with different polymorphic forms of natural type p53
Džiugys et al. Simplified model of Covid-19 epidemic prognosis under quarantine and estimation of quarantine effectiveness
EP0945815A3 (en) Method and system for assessing risks and prognoses of a given course of medical treatment
WO2003062943A3 (en) Method for analyzing data to identify network motifs
Zhao et al. Modeling infection spread and behavioral change using spatial games
WO2002096131A3 (en) System and method for maintaining object data in a distributed object system
Gabbe et al. Profile, transport and outcomes of severe burns patients within an inclusive, regionalized trauma system
WO2003009526A3 (en) Distributed element network management
Lamarca et al. Phylodynamic analysis of SARS-CoV-2 spread in Rio de Janeiro, Brazil, highlights how metropolitan areas act as dispersal hubs for new variants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001945251

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2415832

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 502695

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 67520/01

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10297338

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001945251

Country of ref document: EP